Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
566-03-004 ISMRM Abstract

Multi-sequence MRI Radiomic Model for Non-Invasive Classification of Molecular Subtypes of Posterior Fossa Ependymoma

Primary: Neuro - Tumors
Secondary: Analysis Methods - Radiomics
566-03-004 · Radiomics Potpourri · Wednesday, 13 May, 1:40 PM–2:35 PM · Digital Posters Row G
Accepted
Rui Xu, Pahati Tuxunjiang1,2, Wei Zhao1,2,3,4, Hanjiaerbieke Kukun1,2, Jingming Jiang5, Yuhui Xiong 6, Ainikaerjiang Aihemaiti7, Sijia LI, Yuchen Liu6,8, Yimuran · Subi7, Yunling Wang7
1The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
2Imaging Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
3The Fourth Affiliated Hospital of Xinjiang Medical University, China
4Imaging Center, The Fourth Affiliated Hospital of Xinjiang Medical University, China
5Department of Medical Imaging, The First Affiliated Hospital of Xinjiang Medical University, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
6GE HealthCare MR Research, Beijing, China
7Department of Radiology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
8GE Healthcare, Beijing, China
Presenting Author: Yuhui Xiong

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Seo SH, Paul SK, Shikder M, et al. An Insight into Pathophysiological Features and Therapeutic Advances on Ependymoma. Cancers (Basel). 2021;13(13):3221. Published 2021 Jun 28. doi:10.3390/cancers13133221 [doi]
2. Neumann JE, Spohn M, Obrecht D, et al. Molecular characterization of histopathological ependymoma variants. Acta Neuropathol. 2020;139(2):305-318. doi:10.1007/s00401-019-02090-0 [doi]
3. Lin FY, Chintagumpala M. Advances in Management of Pediatric Ependymomas. Curr Oncol Rep. 2015;17(10):47. doi:10.1007/s11912-015-0470-0 [doi]
4. Bakes E, Cheng R, Mañucat-Tan N, Ramaswamy V, Hansford JR. Advances in molecular prognostication and treatments in ependymoma. J Neurooncol. 2025;172(2):317-326. doi:10.1007/s11060-024-04923-9 [doi]
5. Łastowska M, Matyja E, Sobocińska A, et al. Transcriptional profiling of paediatric ependymomas identifies prognostically significant groups. J Pathol Clin Res. 2021;7(6):565-576. doi:10.1002/cjp2.236 [doi]
6. Cavalli FMG, Hübner JM, Sharma T, et al. Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathol. 2018;136(2):227-237. doi:10.1007/s00401-018-1888-x [doi]
7. Cui Z, Ren G, Cai R, et al. MRI-based texture analysis for differentiate between pediatric posterior fossa ependymoma type A and B. Eur J Radiol. 2022;152:110288. doi:10.1016/j.ejrad.2022.110288 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/566-03-004